Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors.

被引：0
|
作者：
Tolcher, Anthony W.
Victoria, Ivan
Germann, Nathalie
Luecke, Stephan
Bailey, Mark
Kordes, Maximilian
机构：
[1] NEXT Oncol, San Antonio, TX USA
[2] Hosp Clin Barcelona, Barcelona, Spain
[3] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[5] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[6] Karolinska Univ Hosp, Solna, Sweden
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2688
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.
    Gort, Eelke
    Johnson, Melissa Lynne
    Hwang, Jimmy J.
    Pant, Shubham
    Dunzinger, Ulrich
    Riemann, Kathrin
    Kitzing, Thomas
    Janne, Pasi A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors.
    Gutierrez, Martin
    Hamid, Omid
    Shum, Elaine
    Wise, David R.
    Balar, Arjun Vasant
    Weber, Jeffrey S.
    LoRusso, Patricia
    Shafi, Saba
    Rimm, David L.
    Tolcher, Anthony W.
    Basudhar, Debashree
    Dujka, Melanie Elizabeth
    Heller, Kevin N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    [J]. CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [4] Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.
    Ho, A. L.
    Bendell, J. C.
    Cleary, J. M.
    Schwartz, G. K.
    Burris, H. A.
    Oakes, P.
    Agbo, F.
    Barker, P. N.
    Senderowicz, A. M.
    Shapiro, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.
    Gutierrez, Martin
    Janku, Filip
    Tian, Linjie
    Luke, Jason J.
    Shum, Elaine
    Shin, John
    Weiss, Ido
    Liu, Linda N.
    Files, Dallas
    Langermann, Solomon
    Myint, Han
    Bilusic, Marijo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors.
    Park, Jong Chul
    Butler, Marcus O.
    Curti, Brendan D.
    Emens, Leisha A.
    Pastor, Danielle M.
    Elassal, Joseph
    Kaufman, Howard L.
    Kirkwood, John M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5/6 inhibitor, BI 905677, in patients with advanced solid tumors.
    Elez, Elena
    Lenz, Heinz-Josef
    de Jonge, Maja
    Yaeger, Rona
    Doi, Toshihiko
    Pronk, Linda
    Teufel, Michael
    Marzin, Kristell
    Tabernero, Josep
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [8] A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.
    Papadopoulos, K. P.
    Mendelson, D. S.
    Tolcher, A. W.
    Patnaik, A.
    Burris, H. A.
    Rasco, D. W.
    Bendell, J. C.
    Gordon, M. S.
    Kato, G.
    Wong, H.
    Bomba, D.
    Lee, S.
    Gillenwater, H. H.
    Woo, T.
    Infante, J. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Phase 1, open-label, dose-escalation study of M3814 ± avelumab radiotherapy (RT) in patients (pts) with advanced solid tumors.
    Bendell, Johanna C.
    Shafique, Michael Rahman
    Perez, Bradford
    Chennoufi, Sarah
    Beier, Frank
    Trang, Ky
    Antonia, Scott Joseph
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Park, John J.
    Gao, Bo
    Beecroft, Claire
    Wilkinson, Kate Jessica
    Parsonson, Andrew
    Zhang, Karl
    Yan, Xiangyun
    Wang, Ni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345